Mounjaro medi: the clinical picture behind the medicine making headlines

What the trial data actually showed about tirzepatide

The SURMOUNT-1 trial remains the cornerstone reference. Researchers randomised 2,539 adults with obesity to tirzepatide or placebo over 72 weeks, and the results were striking enough to change how clinicians talk about medical weight management. At 15 mg, participants lost an average of roughly 20–21% of their starting body weight; some analyses put the figure closer to 22.5%. Those are averages (individual results spread above and below) but the scale of the findings drove NICE's decision to recommend tirzepatide for NHS use, which it did in Technology Appraisal TA1026, published in December 2024.

A later head-to-head study, SURMOUNT-5, compared tirzepatide directly against semaglutide 2.4 mg in adults with obesity. Tirzepatide produced greater average weight reduction over 72 weeks. That finding matters when someone is choosing between the two medicines, though which is clinically appropriate depends on far more than a trial average, and that conversation belongs with a prescriber.

The Mounjaro clinical programme involved thousands of adults across the SURMOUNT trials. It is a substantial evidence base, and it is why tirzepatide moved from diabetes treatment to a licensed weight loss medication in the UK in a relatively short time. If you want to read more about the underlying medication, our overview of the Mounjaro medication sets out the full licensed indications and how it sits within UK law.

How tirzepatide works differently from other weight-loss medicines

Most GLP-1 medicines act on a single receptor: the glucagon-like peptide-1 pathway, which slows gastric emptying and signals fullness to the brain. Tirzepatide does that too, but it also activates the glucose-dependent insulinotropic polypeptide (GIP) receptor. The dual action appears to produce stronger appetite suppression and greater weight loss than single-pathway medicines, at least at equivalent dose ranges, which is what SURMOUNT-5 demonstrated in the head-to-head comparison.

In practical terms, people on tirzepatide typically find their appetite falls noticeably, particularly in the early weeks after a dose increase. Food feels less central. Portion sizes that once felt small become manageable. That is the GLP-1 and GIP signalling working together, slowing the rate at which the stomach empties and adjusting hunger hormones. The NHS medicines page for tirzepatide describes the mechanism and common side effects clearly, and is worth reading before you start treatment.

Tirzepatide is a Black Triangle (▼) medicine, meaning the MHRA requires additional monitoring of its safety profile. It is not a signal of unusual danger (many newer licensed medicines carry this status while post-market data accumulates) but it does mean clinicians and patients are encouraged to report any side effects through the Yellow Card scheme at yellowcard.mhra.gov.uk. If you experience severe, persistent stomach pain that radiates to the back, seek medical help promptly; the MHRA has highlighted acute pancreatitis as an infrequent but serious risk with GLP-1 medicines.

Who the licensed criteria cover, and where NHS access currently stands

The UK licence sets the entry point at BMI 30 or above, or BMI 27 or above with at least one qualifying condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, or type 2 diabetes. Lower BMI thresholds apply for people from certain ethnic backgrounds under UK guidance. Having a BMI that meets the criteria does not on its own mean Mounjaro will be prescribed, a prescriber weighs the full clinical picture, including medical history and any contraindications.

NHS access is phased and currently limited. From June 2025, tirzepatide became available through some GP practices for people with a BMI of 40 or above alongside four or more qualifying conditions. A second cohort covering BMI 35–39.9 activated in June 2026. Those who do not yet qualify on the NHS, or who prefer not to wait, can access Mounjaro through a regulated private service following a Mounjaro medical assessment. You can read more about what private Mounjaro treatment costs and what is typically included in the price. For a broader comparison of licensed weight-loss options, our treatment overview sets out the full picture.

One thing worth saying plainly: if you come across a seller offering this medicine without any clinical assessment process, that is a serious red flag. Large-scale seizures of counterfeit weight-loss pens have taken place across the UK, and fake products have caused real harm. The only safe route is a prescription from a registered prescriber, dispensed by a pharmacy you can verify on the GPhC register.

Side effects, storage, and what a real medical review covers

The most common side effects of tirzepatide are gastrointestinal: nausea, loose stools, constipation, indigestion, and burping are all reported, particularly in the first few weeks or after a dose increase. For most people they are mild to moderate and ease as the body adjusts. Injection-site reactions, fatigue, and headache also appear in the trial data. Rare but serious events to be aware of include gallbladder problems, signs of dehydration after severe GI illness, and allergic reactions.

The pen itself needs to live in the fridge between uses. If you take it out briefly (to travel, or to carry in a bag for an afternoon appointment) the SmPC and Patient Information Leaflet give the exact time window, and you can find further detail on how this Mounjaro medicine should be handled and stored. Our prescribers can answer storage questions at consultation, and the FAQs page covers some of the common practical queries.

At nume (at nume) every consultation is read by a GPhC-registered Independent Prescriber, not processed by an algorithm. A pharmacist colleague described it recently as the difference between a system spitting out a result and a clinician actually thinking about your case. It takes a little longer than a yes/no bot, but that is the point. If you would like to find out whether Mounjaro, the medical name tirzepatide is sold under in the UK, is clinically appropriate for you, check your eligibility with a free consultation.